GENETIC POLYMORPHISMS AND SUBSTANCE DEPENDENCE

• US 20110143344A1
• Filed: 11/29/2010
• Published: 06/16/2011
• Est. Priority Date: 03/01/2006
• Status: Abandoned Application

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Bierut, Laura J., Wang, Jen-Chyong C., Goate, Alison M.
• Application Number:
  US12/955,306
• Publication Number:
  US 20110143344A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: C12Q 1/6851 Quantitative amplification
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The invention encompasses methods for identifying subjects at risk for substance dependence by detecting the presence of polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene. The invention also encompasses determining the response of a subject to a therapeutic substance, treating substance dependence in a subject, and evaluating the response of a subject to a substance cessation treatment.

Claims

1. A method for identifying a subject at risk for substance dependence, the method comprising detecting in a sample from the subject the presence of at least one polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene, the polymorphisms having a correlation value of 0.7 or greater with each other, wherein the presence of one of the alleles of the polymorphism is associated with increased risk for substance dependence.

2. The method of claim 1, wherein the at least one polymorphism is selected from the group consisting SNP 1, SNP 2, SNP 3, SNP 6, SNP 11, SNP 12, SNP 15, SNP 17, SNP 19, SNP 23, SNP 30, SNP 31, SNP 32. SNP 40, SNP, 41, SNP 42, SNP 43, SNP 44, SNP 45, SNP46 and a combination thereof.

3. The method of claim 1, wherein the at least one polymorphism is selected from the group consisting of:

SNP 6, wherein the absence of a 22 base pair insertion is associated with increased risk for substance dependence;

SNP 11, wherein the presence of A rather than T is associated with increased risk for substance dependence;

SNP 12, wherein the presence of A rather than G is associated with increased risk for substance dependence;

SNP 15, wherein the presence of G rather than C is associated with increased risk for substance dependence;

SNP 19, wherein the presence of T rather than C is associated with increased risk for substance dependence;

SNP 40, wherein the presence of G rather than A is associated with increased risk for substance dependence;

SNP 41, wherein the presence of G rather than A is associated with increased risk for substance dependence;

SNP 42, wherein the presence of T is associated with increased risk for substance dependence;

SNP 43, wherein the presence of A is associated with increased risk for substance dependence;

SNP 44, wherein the presence of A is associated with increased risk for substance dependence;

SNP 45, wherein the presence of T is associated with increased risk for substance dependence;

SNP 46, wherein the presence of T is associated with increased risk for substance dependence; and

a combination thereof.

4. The method of claim 1, wherein the polymorphism is SNP 6.

5. The method of claim 1, wherein the polymorphism is detected with at least one oligonucleotide that distinguishes between two alternate alleles of the polymorphism.

6. The method of claim 5, wherein the oligonucleotide is used in method selected from the group consisting of an amplification method, a hybridization method, a sequencing method, and a combination thereof.

7. The method of claim 1, wherein the substance dependence is selected from the group consisting of alcohol dependence, cocaine dependence, and heroin dependence.

8. The method of claim 1, wherein the substance dependence is alcohol dependence.

9. A method for determining the response of a subject to a therapeutic substance, the method comprising detecting in a sample from the subject the presence of at least one polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene, wherein the presence of a first allele of the polymorphism is associated with a first response and the presence of a second allele of the polymorphism is associated with a second response.

10. The method of claim 9, wherein the polymorphism has correlation value of 0.7 or greater with the polymorphisms in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene.

11. The method of claim 9, wherein the polymorphism is selected from the group consisting SNP 1, SNP 2, SNP 3, SNP 6, SNP 11, SNP 12, SNP 15, SNP 17, SNP 19, SNP 23, SNP 30, SNP 31, SNP 32. SNP 40, SNP, 41, SNP 42, SNP 43, SNP 44, SNP 45, SNP 46 and a combination thereof.

12. The method of claim 9, wherein the first or second response is selected from the group consisting of sensitivity to the therapeutic substance and adverse reactions due to the therapeutic substance.

13. The method of claim 9, wherein the therapeutic substance is selected from the group consisting of a nicotinic acetylcholine receptor agonist, a nicotinic acetylcholine receptor partial agonist, and a nicotinic acetylcholine receptor antagonist.

14. The method of claim 13, wherein the nicotinic acetylcholine receptor agonist is selected from the group consisting of carbamylcholine, methylcarbamylcholine, epibatidine, epiboxidine, and altinicline.

15. The method of claim 13, wherein the nicotinic acetylcholine receptor partial agonist is selected from the group consisting of varenicline, isopronidine, tropisetron, cytsine, and imidacloprid.

16. The method of claim 13, wherein the nicotinic acetylcholine receptor antagonist is selected from the group consisting of bupropion, hexamethonium, mecamylamine, fluoxetine, and iptakalim.

17. A method for evaluating the response of a subject to a substance cessation treatment, the method comprising determining the level of CHRNA5 messenger RNA in a first and a second sample from the subject, the first sample collected before the start of the substance cessation treatment, the second sample collected during or after the substance cessation treatment, wherein a decreased level of CHRNA5 messenger RNA in the second sample relative to the first sample indicates the subject is responding to the substance cessation treatment.

18. A kit for genotyping a subject for at least one polymorphism in the CHRNA5-CHRNA3-CHRNB4 gene cluster and the CHRNA4 gene, the kit comprising at least one oligonucleotide that distinguishes between two alleles of the at least one polymorphism.

19. The kit of claim 18, wherein the at least one oligonucleotide is selected from the group consisting of:

at least one oligonucleotide that distinguishes between the long allele and the short allele of SNP 6;

at least one oligonucleotide that distinguishes between the A allele and the T allele of SNP 11;

at least one oligonucleotide that distinguishes between the A allele and the G allele of SNP 12;

at least one oligonucleotide that distinguishes between the C allele and the G allele of SNP 15;

at least one oligonucleotide that distinguishes between the C allele and the T allele of SNP 19;

at least one oligonucleotide that distinguishes between the G allele and the A allele of SNP 40;

at least one oligonucleotide that distinguishes between the G allele and the A allele of SNP 41;

at least one oligonucleotide that recognizes the T allele of SNP 42; and

a combination thereof.